Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

$AXLA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $AXLA alert in real time by email
SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 AXCELLA HEALTH INC COMMON STOCK Cusip #05454B105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05454B105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,955,724 Item 6: 0 Item 7: 2,955,724 Item 8: 0 Item 9: 2,955,724 Item 11: 4.010% Item 12: HC Cusip #05454B105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,955,724 Item 8: 0 Item 9: 2,955,724 Item 11: 4.010% Item 12: IN Item 1(a). Name of Issuer: AXCELLA HEALTH INC Item 1(b). Address of Issuer's Principal Executive Offices: 840 MEMORIAL DRIVE THIRD FLOOR CAMBRIDGE, MA 02139 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 05454B105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,955,724 (b) Percent of Class: 4.010% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,955,724 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of AXCELLA HEALTH INC. No one other person's interest in the COMMON STOCK of AXCELLA HEALTH INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. September 8, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on September 8, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of AXCELLA HEALTH INC at August 31, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Get the next $AXLA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AXLA

DatePrice TargetRatingAnalyst
11/16/2021$10.00 → $12.00Buy
Chardan Capital
10/12/2021$6.00Outperform
Noble Capital Markets
9/22/2021$9.00 → $5.00Buy → Neutral
Goldman Sachs
7/30/2021Neutral → Underweight
JP Morgan
7/6/2021$14.00Buy
HC Wainwright & Co.
More analyst ratings

$AXLA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Axcella Announces Reverse Stock Split Effective September 19, 2023

    – AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on Septembe

    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Axcella Granted Patent for Long COVID Fatigue Treatment

    Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue. The patent was issued on August 29, 2023, with anticip

    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Axcella Reports Second Quarter Financial Results and Provides Business Update

    AXA1125 remains the most advanced product to help patients experiencing fatigue post acute COVID-19 The Company continues to pursue a strategic alternative for stakeholders Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. "Patients are seeking relief from Long COVID fatigue. Axcella's proprietary composition of amino acids in AXA1125 in Long COVID fatigue is potentially an important step to help people mainta

    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AXLA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AXLA
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AXLA
 SEC Filings

See more

$AXLA
 Leadership Updates

Live Leadership Updates

See more

  • Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

    Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities.  Werner most recently served as Wo

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Biotechnology: Pharmaceutical Preparations

  • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

    CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Biotechnology: Pharmaceutical Preparations

  • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

    CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Biotechnology: Pharmaceutical Preparations

$AXLA
 Financials

Live finance-specific insights

See more

  • Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

    Phase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory authorities Axcella to present at Long COVID forum co-sponsored by BIO and Solve M.E. Axcella to host a conference call February 16 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. F

    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference

    Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities' 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023. Details for Axcella's participation are as follows: Date:   Thursday, February 16, 2023 Time:   11:20 am Eastern Time Webcast:   https://wsw.com/webcast/svb8/axla/1608786 The conference call webcast will be accessible in the Investors & News section on the company's website at www.axcellatx.com. An archive

    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

    MHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements IND for phase 2b/3 trial submitted to the FDA Axcella to host a conference call Tuesday, January 24 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue. The company reported that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U

    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AXLA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more